Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joinn Laboratories (China) CoSHSE:603127 +3.72%78 PB Ratio is 3.64 as of Aug. 02, 2026, which is 40% below its 10-year median of 6.03. GuruFocus rates SHSE:603127 with a GF Score™ of 78/100 and a GF Value™ of ¥17.43 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Joinn Laboratories (China) Co ranks worse than 73.2% on this metric.
The historical rank and industry rank for Joinn Laboratories (China) Co's PB Ratio or its related term are showing as below:
SHSE:603127'
s PB Ratio Range Over the Past 10 Years
Min: 1.22 Med: 6.03 Max: 30.02
Current: 3.64
During the past 13 years, Joinn Laboratories (China) Co's highest PB Ratio was 30.02. The lowest was 1.22. And the median was 6.03.
SHSE:603127's PB Ratio is ranked worse than 73.2% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.025
vs SHSE:603127: 3.64
During the past 12 months, Joinn Laboratories (China) Co's average Book Value Per Share Growth Rate was 5.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 0.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 29.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 46.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Joinn Laboratories (China) Co was 108.30% per year. The lowest was 0.60% per year. And the median was 32.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Joinn Laboratories (China) Co PB Ratio Related Terms
Joinn Laboratories (China) Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603127 vs TMO, DHR, IDXX: PB Ratio Comparison
For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joinn Laboratories (China) Co PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Joinn Laboratories (China) Co's PB Ratio falls into.
Joinn Laboratories (China) Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Joinn Laboratories (China) Co (SHSE:603127) has a PB Ratio of 3.64 as of Aug. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Joinn Laboratories (China) Co and its competitors. This is 40% below median its historical median of 6.03. Over the past decade, Joinn Laboratories (China) Co's PB Ratio has ranged from 1.22 to 30.02. According to the industry distribution chart, Joinn Laboratories (China) Co ranks #142 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 73.2%.
Is Joinn Laboratories (China) Co's PB Ratio too high?
Joinn Laboratories (China) Co's current PB Ratio of 3.64 is 40% below median its 10-year median of 6.03. Over the past 10 years, this metric has ranged from a low of 1.22 to a high of 30.02. The Medical Diagnostics & Research industry median PB Ratio is 2.03. Joinn Laboratories (China) Co's value of 3.64 is 79.8% above this industry median. Based on the distribution chart, Joinn Laboratories (China) Co ranks #142 out of 194 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Joinn Laboratories (China) Co has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Joinn Laboratories (China) Co's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Joinn Laboratories (China) Co ranks #142 out of 194 companies for PB Ratio. This places Joinn Laboratories (China) Co in the lower half of its industry. The industry median PB Ratio is 2.03. Joinn Laboratories (China) Co's value of 3.64 is 79.8% above this benchmark. Historically, Joinn Laboratories (China) Co's own PB Ratio has ranged from 1.22 to 30.02 over the past decade. While the company's 10-year median is 6.03 vs. the industry median of 2.03, Joinn Laboratories (China) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.03, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Joinn Laboratories (China) Co's current PB Ratio of 3.64 is 79.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Joinn Laboratories (China) Co and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Joinn Laboratories (China) Co's current PB Ratio is 3.64, which is 40% below median its own 10-year median of 6.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joinn Laboratories (China) Co stock overvalued right now?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co (SHSE:603127) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥17.43, compared to a current price of ¥41.54 — trading 138.3% above its estimated fair value. The current PB Ratio is 3.64, which is 40% below median its 10-year median of 6.03 and 79.8% above the Medical Diagnostics & Research industry median of 2.03. Joinn Laboratories (China) Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Joinn Laboratories (China) Co (SHSE:603127), the current PB Ratio is 3.64 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joinn Laboratories (China) Co (SHSE:603127) Overvalued in 2026?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co stock appears to be overvalued.
The current stock price of ¥41.54 is trading 138.3% above its estimated GF Value™ of ¥17.43.
GuruFocus considers Joinn Laboratories (China) Co to be Significantly Overvalued.
Key valuation signals for SHSE:603127:
PB Ratio: 3.64 (40% below median its 10-year median of 6.03)
GF Value™: ¥17.43 vs. price of ¥41.54 (138.3% above fair value)
Industry Position: 79.8% above the Medical Diagnostics & Research median (#142 of 194)
No single metric tells the full story. See the SHSE:603127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Joinn Laboratories (China) Co Ltd is a PRC-based company, along with its subsidiary, it is engaged in contract research organisation (CRO) services. It operates in three segments: Non-clinical studies services offer drug safety assessment, drug metabolism and pharmacokinetics (DMPK) studies, and pharmacology and efficacy studies; Clinical trial & related services provide clinical CRO services, co-managed phase I clinical research units, and bioanalytical servicesl services; and Sales of research models engages in the design, production, breeding and sales of research models, non-human primates and rodents. The majority of revenue comes from the Non-Clinical studies services. Its geographical areas are China, the United States, and Other countries, of which the majority are from China.
78GF Score
Get the complete analysis for SHSE:603127
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603127 has been successfully added to your 
